Recently, Zhang et al. reported that JAK2 inhibitors have a weakened effect during long-term anti-pulmonary fibrosis treatment, but simultaneous inhibition of JAK1 and JAK2 can effectively improve the anti-fibrotic effect. Here, JAK2 is linked to pulmonary fibrosis.